AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
11.12
-1.15 (-9.37%)
At close: Nov 2, 2026, 4:00 PM EST
11.18
+0.06 (0.54%)
After-hours: Nov 2, 2026, 7:55 PM EST
AbCellera Biologics Employees
AbCellera Biologics had 562 employees as of December 31, 2025. The number of employees decreased by 34 or 5.70% compared to the previous year. That makes AbCellera Biologics the 19,195th largest employer in the world and 2,599th in the United States.
Employees
562
Change (1Y)
-34
Growth (1Y)
-5.70%
Revenue / Employee
$117,740
Profits / Employee
-$292,982
Market Cap
3.60B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 562 | -34 | -5.70% |
| Dec 31, 2024 | 596 | 10 | 1.71% |
| Dec 31, 2023 | 586 | 91 | 18.38% |
| Sep 30, 2023 | 630 | 155 | 32.63% |
| Jun 30, 2023 | 590 | 140 | 31.11% |
| Mar 31, 2023 | 525 | 125 | 31.25% |
| Dec 31, 2022 | 495 | 109 | 28.24% |
| Sep 30, 2022 | 475 | 115 | 31.94% |
| Jun 30, 2022 | 450 | 148 | 49.01% |
| Mar 31, 2022 | 400 | 194 | 94.17% |
| Dec 31, 2021 | 386 | 180 | 87.38% |
| Sep 30, 2021 | 360 | 186 | 106.90% |
| Jun 30, 2021 | 302 | 128 | 73.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Iovance Biotherapeutics | 975 |
| Acadia Pharmaceuticals | 798 |
| Xenon Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Relay Therapeutics | 202 |
| Disc Medicine | 165 |
| Parabilis Medicines | 145 |
ABCL News
- 3 days ago - AbCellera initiated with a Buy at Jefferies - TheFly
- 11 days ago - AbCellera to Present at Upcoming Investor Conferences in November 2026 - Business Wire
- 22 days ago - AbCellera initiated with a Buy at UBS - TheFly
- 25 days ago - AbCellera to present Phase 1/2 data for ABCL635 at TMS 2026 Annual Meeting - TheFly
- 25 days ago - AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting - Business Wire
- 4 weeks ago - AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 - Business Wire
- 4 weeks ago - AbCellera initiated with an Overweight at JPMorgan - TheFly
- 5 weeks ago - AbCellera resumed with a Neutral at Goldman Sachs - TheFly